10601 results for 'EGF Receptor Inhibitors'

Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro

Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin

Cell Signalling · Kinase CascadesMAPK Signaling: The Pathway of Mitogen StimulationThe mitogen-activated protein kinase (MAPK) pathway is one of the most important signalling cascades in biology, conv

Protein Analysis · ProtocolsWestern Blot Sample Preparation: A Practical GuideMost failed Western blots fail before the gel is loaded. Lysis buffer choice, inhibitor selection, accurate protein quanti

Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b

Cell Biology · Protein DegradationThe Autophagy Pathway: Mechanism, Regulation and How to Measure ItAutophagy is the cell’s route for degrading and recycling its own contents — damaged organelles, agg

Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm

Immunology · Flow CytometryT Cell Immunophenotyping: Markers, Subsets and Panel DesignImmunophenotyping identifies cell populations by the proteins on their surface. For T cells that means resolving n

Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a

Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo

Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mec

TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy and the treatment of autoimmune diseases. As a checkpoint receptor, TIGIT

By Eoin Mac Réamoinn Toll-like receptors (TLRs) are renowned for their fundamental roles in innate sensing and initiating inflammatory responses. TLRs acco

Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhibi

Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progress

V-domain Ig suppressor of T cell activation (VISTA) is an emerging immune checkpoint receptor that plays a key role in suppressing T cell activity within the tumor microenvironment (TME).

B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role i

The complex interplay between chemokines and cytokines is fundamental to the immune system's function, orchestrating the body's response to infection, inflammation, and injury. This detailed analy

The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi